Okano Yumi, Yamauchi Tomoaki, Fukuzaki Runa, Tsuruta Akito, Yoshida Yuya, Tsurudome Yuya, Ushijima Kentaro, Matsunaga Naoya, Koyanagi Satoru, Ohdo Shigehiro
Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
Department of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
J Biol Chem. 2024 Nov;300(11):107890. doi: 10.1016/j.jbc.2024.107890. Epub 2024 Oct 15.
Malignant cells exhibit a high demand for amino acids to sustain their abnormal proliferation. Particularly, the intracellular accumulation of cysteine is often observed in cancer cells. Previous studies have shown that deprivation of intracellular cysteine in cancer cells results in the accumulation of lipid peroxides in the plasma membrane and induction of ferroptotic cell death, indicating that cysteine plays a critical role in the suppression of ferroptosis. Herein, we found that the oncogenic accumulation of cysteine also contributes to cancer cell proliferation by promoting the cell cycle progression, which is independent of its suppressive effect on ferroptosis. The growth ability of four types of cancer cells, including murine hepatocarcinoma cells, but not of primary hepatocytes, were dependent on the exogenous supply of cysteine. Deprivation of intracellular cysteine in cancer cells induced cell cycle arrest at the G0/G1 phase, accompanied by a decrease in the expression of cyclin D1 and D2 proteins. The cysteine deprivation-induced decrease in D-type cyclin expression was associated with the upregulation of eukaryotic translation initiation factor 4E binding protein 1, which represses the translation of cyclin D1 and D2 proteins by binding to eukaryotic translation initiation factor 4E. Similar results were observed in hepatocarcinoma cells treated with erastin, an inhibitor of cystine/glutamate antiporter, xCT. These findings reveal an unappreciated role of cysteine in regulating the growth of malignant cancer cells and deepen our understanding of the cytotoxic effect of xCT inhibitor to prevent cancer cell proliferation.
恶性细胞对氨基酸有很高的需求以维持其异常增殖。特别是,半胱氨酸在癌细胞内的积累经常被观察到。先前的研究表明,癌细胞内半胱氨酸的缺失会导致质膜中脂质过氧化物的积累并诱导铁死亡细胞死亡,这表明半胱氨酸在抑制铁死亡中起关键作用。在此,我们发现半胱氨酸的致癌性积累还通过促进细胞周期进程来促进癌细胞增殖,这与其对铁死亡的抑制作用无关。四种癌细胞类型(包括小鼠肝癌细胞,但不包括原代肝细胞)的生长能力依赖于半胱氨酸的外源供应。癌细胞内半胱氨酸的缺失诱导细胞周期停滞在G0/G1期,同时伴随着细胞周期蛋白D1和D2蛋白表达的降低。半胱氨酸缺失诱导的D型细胞周期蛋白表达降低与真核翻译起始因子4E结合蛋白1的上调有关,该蛋白通过与真核翻译起始因子4E结合来抑制细胞周期蛋白D1和D2蛋白的翻译。在用胱氨酸/谷氨酸反向转运体xCT的抑制剂艾拉司群处理的肝癌细胞中也观察到了类似的结果。这些发现揭示了半胱氨酸在调节恶性癌细胞生长中的一个未被重视的作用,并加深了我们对xCT抑制剂预防癌细胞增殖的细胞毒性作用的理解。